Safety Analyses of Clinical Data for Bifeprunox in Patients with
Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar
COLLEGEVILLE, Pa., March 30, 2007 /PRNewswire-FirstCall/ --
Wyeth Pharmaceuticals, a division of Wyeth , Solvay
Pharmaceuticals, Inc. and Lundbeck A/S presented clinical study
results on bifeprunox
at an international medical congress this
week. Safety analyses suggest bifeprunox, an investigation...
New Long-Term Data Analyses for Bifeprunox Show Favorable Effects
Versus Placebo in Stabilized Patients with Schizophrenia
Six-Month Data Show Bifeprunox
Significantly Longer than Placebo and had a Favorable Weight and
Lipid Profile Comparable with Placebo
MARIETTA, Ga. and COLLEGEVILLE, Pa., May 22, 2007 - Solvay
Pharmaceuticals, Inc., Wyeth Pharmaceuticals, a division of Wyeth
(NYSE:WYE), and ...
Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
...e at this time. The FDA stated in the letter that bifeprunox
in the long-term mainte...e claim for
bifeprunox. The Companies believe that bifeprunox
offers distinct benefits
for the long-term mainten...ce indication. Although the FDA acknowledged that bifeprunox
separated from placebo in
two short-term studies i...